

**For Immediate Release
February 26, 2013**

**Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer
Drug Candidate, Adva-27a**

Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to provide an update on the progress of the IND-Enabling studies of Adva-27a, the Company's flagship oncology drug candidate. To date, the Company has completed seven in vitro studies in which Adva-27a has shown potent anti-tumor activity in every cell line tested, including multidrug resistant breast cancer, multidrug resistant uterine cancer and small-cell lung cancer, for which today's approved therapies have little or no efficacy.

The Adva-27a IND-Enabling research is being conducted in the United States and Canada. Following filing of the IND application, the clinical trials are scheduled to be performed at McGill University's world-renowned Jewish General Hospital in Montreal, Canada.

"We are extremely excited about the laboratory data that have been collected so far, which have shown Adva-27a to have a robust profile in destroying tumors in a wide array of cancer lines that have very limited, if any, treatment options today," said Dr. Steve N. Slilaty, President and Chief Executive Officer of Sunshine Biopharma. "The next wave of studies is progressing as planned and we look forward to analyzing and delivering these results to our shareholders in the near future. While no assurances can be provided, we are very optimistic that the new data will support and validate the in vitro studies as we develop what we believe could be a monumental breakthrough in oncology."

About Breast Cancer

The National Cancer Institute ("NCI") estimates that 232,340 women and 2,240 men in the United States will be diagnosed with breast cancer in 2013. According to the NCI website, approximately 40,000 deaths in 2013 will be attributed to breast cancer, making it the second leading cause of cancer related deaths in women in the United States. Globally, 1.38 million new cases of breast cancer were diagnosed in 2008 and 458,000 deaths resulted from the disease, according to the World Health Organization. One of the most commonly used drugs to treat breast cancer today is Herceptin® (trastuzumab), a therapeutic of Roche Holding AG designed to treat patients with HER-2 (Human Epidermal Growth Factor Receptor 2) positive form of the disease. This condition is present in approximately 20 percent of breast cancer patients. Sales of Herceptin® in 2012 were approximately \$6 billion worldwide.

About Sunshine Biopharma Inc.

Sunshine Biopharma is a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma's parent company, Advanomics Corporation, recently announced that it has filed a new patent application covering various composition matters and manufacturing processes of Adva-27a.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO

Sunshine Biopharma Inc.

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com